RE: Goldman Sachs26 Sep 2023 15:20
Hi RagstoRich
Ok let me try to explain it again in your terms -:
NM offer:
315M shares in issue, £2.75 per share = £866M value
Pre-dividend value:
315M shares in issue, £2.18 per share = £687M value
Post divi value (now):
Dividend payout: £362M (£1.15 per share)
Share buy-back to date £12M
143M shares in issue, £1.76 per share = £251M
So you have:
Total delivered value to date: £625M (div + buy-back+ current SP)
NewMed deal: £866M
Thus there has been £241M of value destruction. Still a colossal amount!!
--------------------------
And there will be more "value destruction" to come via the share consolidation & the rest of the share buy-back.
--------------------------
The difference is that you call it "value destruction" RagstoRich, I don't.
Have they sold Egypt on the cheap ? given away the future UK contingent payments to anyone else, or the possible Senegal one ? No
What they've done is stop any more expenditure on Mexico, the other UK licences it had & the other exploration stuff.
Were these given any real value in the NewMed offer ? No
So where's the missing £241M of value ?
Well its still in the company, in the form of the 3 assets I listed earlier, plus the £80M of cash that is about to be paid out, the rest of the buy-back cash £8M, the working cash in the Egypt business & the difference between receivables & payables.
Once you get your head around that point, (that it's still there in plain sight) the rest all makes sense.
The Shell Payment $25M & the exploration costs in Egypt would all have been factored into the NewMed offer as they were known about as would most if not all of the development expenditure that's taken place in Egypt.
Now you could argue that some of the "missing money" figure should be reduced a little because of Woodside's delay of getting Senegal up & running & yes it could end up at nil & I have no problem if you want to take that view in getting to the valuation of the parts.
The only difference is the value hidden in plain sight as I call it is now going to be shared out amongst far fewer share's.
On top of which the company's G&A expenses are going to be £40M lower each year going forward & that's something that wouldn't have been factored into the NewMed offer. This is a significant annual bonus that the market is not recognising for now.
So in summary - If NewMed were to make that same offer or a similar one come the 6th of October using the same criteria as before, for the assets still in the company it would be for roughly £400M (£850M less £454M paid out in cash & buyback [£362M, £80M + £12M]) which with 95.2M shares left in issue works out at over £4 per share instead of £2.70 previously.
I hope that clarifies everything for you RagstoRich
LOTM